Tramofal Plus Mechanism of Action

Tramadol is a synthetic opioid analgesic with centralized action. Although the action is not fully known, from the results of tests on animals, at least two complementary mechanisms can be applied. Binding of the parent and metabolite of M1 μ-opioid receptors and a weak inhibition of the recovery of Norepinephrine and Serotonin. Opioid activity is due to both the binding affinity of the parent compound being low and the binding affinity of the O-demethylated M1 metabolite to be a higher μ-opioid receptor. In experimental animals, M1 accounts for 6x more potent than Tramadol in producing analgesics and 200 times more potent in μ-opioid binding. Tramadol-analgesic is induced only partially opposite by opiate antagonists Naloxone in several tests in experimental animals. The relative contribution of both Tramadol and M1 to human analgesia depends on the plasma concentration of each component.
Tramadol has been shown to inhibit in vitro retrieval of norepinephrine and Serotonin, such as other opioid analgesics. This mechanism can contribute freely to the overall analgesic profile of Tramadol. In addition to analgesics, administration of Tramadol can cause several symptoms (including dizziness, somnolence, nausea, constipation, sweating and pruritus), similar with other opioids.
Paracetamol is a non-opioid and non-salicylic analgesic.